UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 14C INFORMATION

 

Information Statement Pursuant to Section 14(c)

of the Securities Exchange Act of 1934

 

Check the appropriate box:

 

Preliminary Information Statement
   
Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
   
Definitive Information Statement   
   
Definitive Additional Materials

 

YEW BIO-PHARM GROUP, INC.

(Name of Registrant as Specified In Its Charter)

 

Payment of Filing Fee (Check the appropriate box):

 

No fee required.
   
Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

 

  1) Title of each class of securities to which transaction applies:

 

2) Aggregate number of securities to which transaction applies:

 

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

 

4) Proposed maximum aggregate value of transaction:

 

5) Total fee paid:

 

Fee paid previously with preliminary materials.
   
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

1) Amount Previously Paid:

 

2) Form, Schedule or Registration Statement No.:

 

3) Filing Party:

 

4) Date Filed:

 

 

 

 

 

 

YEW BIO-PHARM GROUP, INC.

 

9460 Telstar Avenue, Suite 6

El Monte, California 91731

 

NOTICE OF INTERNET AVAILABILITY OF INFORMATION STATEMENT MATERIALS

AND

FORM 10-K FOR THE YEAR 2019

 

To Our Stockholders:

 

An Information Statement is being made available by the Board of Directors of Yew Bio-Pharm Group, Inc., a Nevada corporation (the “Company”), to holders of record of the Company’s common stock at the close of business on September 28, 2020 (the “Record Date”). The purpose of this Information Statement is to inform the Company stockholders of the following actions taken by written consent of the holders of a majority of the Company’s voting stock, dated September 28, 2020:

 

1. To elect seven (7) directors to serve until the next Annual Meeting of Shareholders and thereafter until their successors are elected and qualified; and

 

2. To grant the Board of Directors the discretionary authority to amend the Company’s articles of incorporation to affect a reverse stock split (the “Reverse Split Proposal”) of the Company’s common stock (“Common Stock”); and

 

3. A proposal to ratify the appointment of Simon & Edward, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.

 

The foregoing actions were approved on September 28, 2020 by our Board of Directors. In addition, on September 28, 2020 the holders of 52.1% of the Company’s outstanding voting securities, as of the Record Date approved the foregoing actions. The number of shares voting for the proposals was sufficient for approval.

 

Section 78.320 of the Nevada Revised Statutes (the “NRS”) provides in part that any action required or permitted to be taken at a meeting of the stockholders may be taken without a meeting if, before or after the action, a written consent thereto is signed by stockholders holding at least a majority of the voting power, except that if a different proportion of voting power is required for such an action at a meeting, then that proportion of written consents is required.

 

Important Notice Regarding the Availability of Information Statement Materials and the Form 10-K

 

Pursuant to Securities and Exchange Commission Rule §240.14C-2, you are receiving this notice that the Information Statement and Annual report on Form 10-K are available on the Internet. This communication provides only a brief overview of the more complete Information Statement Materials. We encourage you to access and review all of the important information contained in the Information Statement Materials.

 

Follow the instructions below to view the materials or request printed or email copies.

 

Our Information Statement and Annual Report on Form 10-K for the fiscal year ended December 31, 2019, are available at www.yewbiopharm.com/investors/annual-meeting/

 

If you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting a paper or e-mail copy. Please make your request for a copy by one of the following methods on or before October 23, 2020 to facilitate timely delivery.

 

- E-mail to hpang@yewbiopharm.com

 

- Mail at Yew Bio-Pharm Group, Inc., 9460 Telstar Avenue, Suite 6, El Monte, CA 91731

 

- Telephone call to (626) 401-9588.

 

WE ARE NOT ASKING FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

 

  By Order of the Board of Directors,
   
  /s/ Zhiguo Wang
  Zhiguo Wang, Chief Executive Officer
  Dated: October 13, 2020

  

 

 

 

Yew Bio Pharm (QB) (USOTC:YEWB)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Yew Bio Pharm (QB) Charts.
Yew Bio Pharm (QB) (USOTC:YEWB)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Yew Bio Pharm (QB) Charts.